



Release no 53

19 October 2001

Suspension of Serdolect[®] lifted

On its meeting 18 October 2001 the Committee for Proprietary Medicinal Products (CPMP) decided to lift the suspension of Serdolect[®] (sertindole) - H. Lundbecks drug for the treatment of Schizophrenia.

Serdolect was launched in 1996, but was suspended due to concerns about the product's safety profile. The revocation of the suspension is based on additional pre-clinical and clinical data, all of which is supporting the safety of Serdolect[®].

In connection with the withdrawal of the suspension Lundbeck has agreed to undertake post-marketing clinical studies, which will include patients treated with Serdolect[®]. This means that Serdolect[®] will not be available for normal prescription until at a later stage, presumably 2003.

"I have always been firmly convinced that Serdolect[®] is a safe and efficient drug that will truly improve the quality of life for many patients suffering from Schizophrenia", says President and CEO of Lundbeck, Erik Sprunk-Jansen and continues, "It therefore gives me great pleasure that the drug will now again be available to patients".

Lundbeck hold the global rights to market Serdolect[®].

The content of this release will not influence the Lundbeck Group's expectations for the financial result 2001.

For further information please contact Hans Henrik Munch-Jensen, CFO, tel +45 36 30 15 11, ext. 2660.

H. Lundbeck A/S

Ottiliavej 9
DK-2500 Valby Copenhagen Fax +45 36 30 57 42

Tel +45 36 30 13 11

E-mail information@lundbeck.com
www.lundbeck.com



Shareholders, financial analysts, representatives of banks and brokerage firms and other investment professionals should address inquiries to Steen Juul Jensen, Director of Corporate Communication & Investor Relations, tel +45 36 30 13 11, ext. 3006.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2000 the Company's revenue was DKK 5.6 billion and the number of employees approx. 3,500 people. For more information about Lundbeck please visit www.lundbeck.com.